Today, ChromaDex Corporation (https://www.chromadex.com/)
(NASDAQ:CDXC), an innovator of proprietary health, wellness
and nutritional ingredients that creates science-based solutions
for dietary supplement, food and beverage, skin care, sports
nutrition, and pharmaceutical products, is announcing the official
grand opening of its new 10,000-square-foot research and
development center in Longmont, Colorado.
With nearly $1 million invested to renovate the
space into a state-of-the-art facility, it now includes multiple
laboratories which will support the discovery and development of
novel molecules and compounds to add to ChromaDex’s proprietary
ingredient portfolio, while also allowing for the expansion of
ChromaDex’s analytical service offerings at its Boulder, Colorado,
location.
The grand opening ceremony will be held today,
Thursday, January 5th, with Longmont Mayor, Dennis L. Coombs, as
well as members from the Longmont Economic Development Partnership
and ChromaDex Corporation in attendance.
Chief Operating Officer, Troy Rhonemus
commented, “The construction and opening of the Longmont R&D
facility marks an important growth milestone for ChromaDex. This
facility is a critical asset that will enable us to acquire
additional ingredient intellectual property, and continue our
leadership in the identification and development of additional NAD+
metabolites.”
Nicotinamide adenine dinucleotide (NAD+) is an
essential coenzyme in cellular metabolism. Published research
suggests that many aging-related health challenges are linked to
NAD+ deficiency. NAD+ and its metabolites such as NR have
been the focus of intense scientific research and popular news
media coverage recently due to their believed roles in healthy
aging and healthspan. NR has been shown to safely and
effectively increase NAD+ in humans supported by published research
in Nature Communications.
ChromaDex, being publicly traded on NASDAQ,
gives the public an opportunity for investing in the business of
science-based technologies for healthy aging and longevity. To
date, ChromaDex has invested millions in safety, toxicology and
human clinical trials on NR. It has also has initiated over 100
collaborative studies with leading universities and research
institutions such as the National Institute of Aging, MIT and the
Scripps Research Institute representing an estimated $40-50 million
in NR research. Most of ChromaDex’s recent revenue growth has
come from its proprietary ingredients, in particular NIAGEN®, which
is commercially manufactured NR by ChromaDex.
Frank Jaksch Jr., Founder and CEO of ChromaDex,
stated, “These collaborative studies are a huge validation that NR
is very much relevant to the research community, as many of these
collaborations that started as preclinical animal studies are now
being published in top tier peer-reviewed journals such as Nature,
Science and Cell Metabolism. We are now moving into human clinical
studies based on the preclinical success of NR.”
ChromaDex’s current proprietary ingredient
portfolio is backed with clinical and scientific research, as well
as extensive IP protection. In addition to NIAGEN®, NR, ChromaDex
also has pTeroPure® pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and
AnthOrigin™, naturally extracted anthocyanins, in its portfolio of
patented technologies.
For more information on ChromaDex, visit:
https://www.chromadex.com/.
About ChromaDex:ChromaDex
leverages its complementary business units to discover, acquire,
develop and commercialize patented and proprietary ingredient
technologies that address the dietary supplement, food, beverage,
skin care and pharmaceutical markets. In addition to our ingredient
technologies unit, we also have business units focused on natural
product fine chemicals (known as "phytochemicals"), chemistry and
analytical testing services, and product regulatory and safety
consulting (known as Spherix Consulting). As a result of our
relationships with leading universities and research institutions,
we are able to discover and license early stage, IP-backed
ingredient technologies. We then utilize our in-house chemistry,
regulatory and safety consulting business units to develop
commercially viable ingredients. Our ingredient portfolio is backed
with clinical and scientific research, as well as extensive IP
protection. Our portfolio of patented ingredient technologies
includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene;
PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a
spirulina extract; and AnthOrigin™, anthocyanins derived from a
domestically-produced, water-extracted purple corn. To learn more
about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to the asset’s ability to
support the discovery and development of new molecules, ingredients
and intellectual property. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended January 2, 2016, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024